Published in Crit Care on September 19, 2005
Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus (2009) 1.05
Blood coagulation disorders in septic patients. Wien Med Wochenschr (2010) 1.00
Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care (2006) 0.97
Antithrombin in sepsis revisited. Crit Care (2005) 0.78
A latent class approach for sepsis diagnosis supports use of procalcitonin in the emergency room for diagnosis of severe sepsis. BMC Anesthesiol (2013) 0.77
Year in review 2005: Critical Care - resource management. Crit Care (2006) 0.75
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost (2001) 6.16
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA (2001) 5.86
Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest (1992) 2.80
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med (2004) 2.24
Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med (1998) 2.12
High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med (2006) 2.07
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med (2001) 1.97
Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med (2004) 1.66
Clinical trial design and outcomes in patients with severe sepsis. Shock (2003) 1.57
Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol (2004) 1.55
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost (2001) 0.95
Current drug treatment strategies for disseminated intravascular coagulation. Drugs (1998) 0.92
Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res (1998) 0.89
Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost (2002) 0.88
Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med (2000) 0.83
Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol (1999) 0.81
Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis. Lancet (1997) 0.80
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med (2009) 4.13
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol (2014) 3.06
Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med (2015) 2.97
Year in review in Intensive Care Medicine 2011: III. ARDS and ECMO, weaning, mechanical ventilation, noninvasive ventilation, pediatrics and miscellanea. Intensive Care Med (2012) 2.52
Parthenolide and its photochemically synthesized 1(10)Z isomer: chemical reactivity and structure-activity relationship studies in human leucocyte chemotaxis. Bioorg Med Chem (2003) 2.16
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant (2014) 2.10
Evaluation and initial management of acute kidney injury. Clin J Am Soc Nephrol (2008) 1.83
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
Marburg I polymorphism of factor VII--activating protease: a prominent risk predictor of carotid stenosis. Circulation (2003) 1.77
Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med (2013) 1.75
The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives. BMC Med Genet (2007) 1.64
Direct percutaneous access technique for transaxillary transcatheter aortic valve implantation: "the Hamburg Sankt Georg approach". JACC Cardiovasc Interv (2012) 1.60
Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost (2006) 1.59
Arrhythmias and increased neuro-endocrine stress response during physicians' night shifts: a randomized cross-over trial. Eur Heart J (2009) 1.55
Histologic pathologies of the myocardium in septic shock: a prospective observational study. Shock (2013) 1.55
Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol (2004) 1.50
Disturbances of electrolytes and blood chemistry in acute alcohol intoxication. Wien Klin Wochenschr (2005) 1.47
Expression and function of the endothelial protein C receptor in human neutrophils. Blood (2003) 1.45
Co-infection with two Chlamydophila species in a case of fulminant myocarditis. Crit Care Med (2007) 1.43
Case involving end-of-life decision issues in Italy. Intensive Care Med (2007) 1.43
Improving outcomes from acute kidney injury. J Am Soc Nephrol (2007) 1.42
Mortality after hydroxyethyl starch 130/0.4 infusion: an updated meta-analysis of randomized trials. Swiss Med Wkly (2012) 1.41
Perspectives in economic analyses of sepsis. Wien Klin Wochenschr (2002) 1.40
Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulation. Intensive Care Med (2012) 1.39
First-in-man transcatheter mitral valve-in-ring implantation with a repositionable and retrievable aortic valve prosthesis. EuroIntervention (2016) 1.39
Increasing evidence base for sodium bicarbonate therapy to prevent contrast media-induced acute kidney injury: little role of unpublished studies. Nephrol Dial Transplant (2009) 1.39
Improving outcomes of acute kidney injury: report of an initiative. Nat Clin Pract Nephrol (2007) 1.38
Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process. Clin J Am Soc Nephrol (2008) 1.30
Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol (2009) 1.29
Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother (2006) 1.20
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Intensive Care Med (2014) 1.17
Albumin replacement in severe sepsis or septic shock. N Engl J Med (2014) 1.16
Improving outcomes from acute kidney injury: report of an initiative. Pediatr Nephrol (2007) 1.15
Toll-like receptor 4 and atherogenesis. Ann Med (2003) 1.12
Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med (2015) 1.12
Migration of human monocytes in response to procalcitonin. Crit Care Med (2002) 1.11
Patient Selection and Timing of Continuous Renal Replacement Therapy. Blood Purif (2016) 1.10
Radiocontrast-induced acute kidney injury in the ICU: worse than presumed? Intensive Care Med (2011) 1.10
Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med (2010) 1.09
Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Med (2007) 1.08
Concerns about renal safety of HES 130. Crit Care (2013) 1.07
Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clin Pharmacokinet (2012) 1.07
Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care (2011) 1.06
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J (2008) 1.06
Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. J Immunol (2006) 1.06
Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med (2012) 1.06
Resuscitation with hyperoncotic colloids in the intensive care unit. Intensive Care Med (2008) 1.05
Dietary poisoning with Veratrum album--a report of two cases. Wien Klin Wochenschr (2005) 1.02
Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr (2008) 1.01
The PIRO concept: P is for predisposition. Crit Care (2003) 1.00
Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother (2013) 0.99
Use of the pulmonary artery catheter is not associated with worse outcome in the ICU. Chest (2005) 0.99
Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol (2003) 0.99
Influence of albumin dialysis on pharmacokinetics of amphotericin B colloidal dispersion and amphotericin B lipid complex. Artif Organs (2011) 0.99
Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl (2013) 0.98
The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation (2004) 0.98
Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care (2010) 0.98
Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab (2005) 0.98
Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr Protein Pept Sci (2005) 0.97
Biomarkers and acute kidney injury: dining with the Fisher King? Intensive Care Med (2009) 0.97
Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori (2007) 0.97
Hydroxyethyl starch 130/0.4: safe for the kidney in surgical patients? Anesthesiology (2013) 0.96
Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum (2004) 0.96
Genetic and acquired inflammatory conditions are synergistically associated with early carotid atherosclerosis. Stroke (2006) 0.95
Expression and function of the angiopoietin receptor Tie-2 in human eosinophils. J Allergy Clin Immunol (2004) 0.95
Inhibition of thrombin-induced signaling by resveratrol and quercetin: effects on adenosine nucleotide metabolism in endothelial cells and platelet-neutrophil interactions. Thromb Res (2004) 0.94
Pharmacokinetics of liposomal amphotericin B during extracorporeal albumin dialysis. Artif Organs (2006) 0.94
The European Clinical Trials Directive revisited: the VISEAR recommendations. Resuscitation (2006) 0.94
Year in review in Intensive Care Medicine 2009. Part III: mechanical ventilation, acute lung injury and respiratory distress syndrome, pediatrics, ethics, and miscellanea. Intensive Care Med (2010) 0.93
Penetration of amphotericin B lipid formulations into pleural effusion. Antimicrob Agents Chemother (2007) 0.93
The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB J (2004) 0.93
Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood (2003) 0.93
Migration of leukocytes across an endothelium-epithelium bilayer as a model of renal interstitial inflammation. Am J Physiol Cell Physiol (2007) 0.92
Chloride-restrictive fluid administration and incidence of acute kidney injury. JAMA (2013) 0.91
Angiopoietin affects neutrophil migration. Microcirculation (2005) 0.91
Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther (2007) 0.89
Year in review in Intensive Care Medicine 2009: I. Pneumonia and infections, sepsis, outcome, acute renal failure and acid base, nutrition and glycaemic control. Intensive Care Med (2010) 0.89
Recommendations on therapy limitation and therapy discontinuation in intensive care units: Consensus Paper of the Austrian Associations of Intensive Care Medicine. Intensive Care Med (2008) 0.88
Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol (2002) 0.88
Renal replacement therapy: to treat, or not to treat, that is the question... Crit Care (2013) 0.88
Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster. Hum Mol Genet (2011) 0.88